SCHEMBL5256274

SCHEMBL5256274

CC(C)(C)c1cccc(-n2cc(-c3ccc4ccccc4n3)cn2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.40
EPHX2 P34913 1/20 0.40
MKNK1 Q9BUB5 5/20 0.39
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
PDE10A Q9Y233 1/20 0.39
GRM4 Q14833 1/20 0.38
NPC1 O15118 7/20 0.38
RAB9A P51151 7/20 0.38
KDM4E B2RXH2 4/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
MAPT P10636 2/20 0.38
XBP1 P17861 1/20 0.38
KLF5 Q13887 1/20 0.38
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
AR P10275 2/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5216133 0.86 GRM5 (0.42) GRM5EPHX2MKNK1KEAP1NFE2L2
SCHEMBL5215415 0.83 GRM2 (0.43) GRM5EPHX2MKNK1KEAP1NFE2L2
SCHEMBL5218685 0.82 GRM5 (0.42) GRM5MKNK1PDE10AGRM4
SCHEMBL8357392 0.82 MKNK1 (0.46) GRM5MKNK1PDE10AGRM4NPC1
SCHEMBL5215983 0.79 MKNK1 (0.42) GRM5MKNK1PDE10AGRM4NPC1
SCHEMBL3917705 0.79 GRM5 (0.62) GRM5EPHX2MKNK1KEAP1NFE2L2
SCHEMBL30794399 0.79 GRM5 (0.62) GRM5EPHX2MKNK1KEAP1NFE2L2
SCHEMBL5216979 0.79 NPC1 (0.44) PDE10ANPC1RAB9AKDM4ESMN1; SMN2
SCHEMBL182218 0.78 NPC1 (0.55) GRM5KEAP1NFE2L2NPC1RAB9A
SCHEMBL14381223 0.77 MKNK1 (0.42) GRM5MKNK1PDE10AGRM4NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1458383-B1 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2007-11-21 EP claimed
EP-1458383-A4 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO INC (US) 2005-05-25 EP claimed
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK SHARP & DOHME LLC 2005-02-03 US claimed
EP-1458383-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 Merck & Co., Inc. (US) 2004-09-22 EP claimed
WO-2004030637-A2 TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE MERCK & CO., INC. (US) 2004-04-15 WO claimed
WO-2003051833-A2 HETEROARYL SUBSTITUTED PYRAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 MERCK & CO., INC. (US) 2003-06-26 WO claimed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed
US-7569592-B2 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 MERCK & CO., INC. (US) 2009-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026963-A1 Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 GRM5, GRIK5, GRIN2C GRM5 1/4885EPHX2 3429/4885MKNK1 893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.